---
layout: default
title: Atazanavir
parent: 僅模型預測 (L5)
nav_order: 31
evidence_level: L5
indication_count: 6
---

# Atazanavir
{: .fs-9 }

證據等級: **L5** | 預測適應症: **6** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Atazanavir: Drug Repurposing Evaluation — Insufficient Data for Prediction

## One-Sentence Summary

Atazanavir (DB01072) is an HIV-1 protease inhibitor used in antiretroviral therapy.
The current Evidence Pack contains **no TxGNN predicted indications**, and critical data including mechanism of action, safety warnings, and contraindications are absent.
This evaluation cannot proceed to clinical relevance assessment until the identified data gaps are resolved.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | HIV-1 infection (general knowledge; not confirmed in Evidence Pack) |
| Predicted New Indication | No prediction available |
| TxGNN Prediction Score | Not available |
| Evidence Level | L5 — No predictions generated |
| Finland Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

No TxGNN predicted indications are present in this Evidence Pack. The `predicted_indications` field is an empty array, meaning the drug repurposing model has not generated any candidate new indications for Atazanavir at this time. Without at least one prediction, the core purpose of this evaluation — assessing a novel repurposing hypothesis — cannot be fulfilled.

Mechanism of action data is also flagged as a high-severity data gap. Package insert warnings and contraindications from the regulatory source query returned a result but were not parsed into structured fields. Without a confirmed MOA and safety baseline, no mechanistic bridge between any original indication and a hypothetical new indication can be constructed.

Atazanavir is broadly recognised as an HIV-1 protease inhibitor that prevents viral polyprotein maturation. This general knowledge is noted for context only and does not substitute for structured Evidence Pack data required by this evaluation framework.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack contains no TxGNN predicted indications and three blocking or high-severity data gaps; there is no repurposing hypothesis to evaluate, and the safety baseline required for any further assessment is missing.

**To proceed, the following is needed:**

- **TxGNN prediction run**: Re-execute the TxGNN pipeline for DB01072 to populate `predicted_indications`; the array is currently empty
- **Mechanism of action (MOA)**: Query the DrugBank API for DB01072 to retrieve pharmacodynamic and target data
- **Package insert warnings & contraindications**: Parse the TFDA/EMA package insert PDF (query log shows a successful fetch but no structured output) into `key_warnings` and `contraindications` fields
- **Drug-drug interaction (DDI) data**: The DDI query returned `not_found`; re-query with alternate identifiers or a broader DDI database
- **Finland market authorisation status**: Verify against the EMA/Fimea registry, as the current `market_status` of "Not marketed" may reflect a Taiwan-registry query rather than a Finnish-market query
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

